Overview

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hui Bu

Treatments:

Durvalumab
Methotrexate

Criteria

Inclusion Criteria:

1. Male and Female age 18 or more

2. Pathologically proven non-small cell lung cancer

3. MRI(Magnetic Resonance Imaging,MRI) imaging findings or the detection of malignant
cells in cerebrospinal fluid

4. Patients have the ability to understand and the willingness to sign a written informed
consent document.

Exclusion Criteria:

1. KPS score <60

2. History of autoimmune diseases

3. With severe hepatic and renal dysfunction

4. Has a history of (non-infectious) pneumonitis that required steroids